PerkinElmer, Inc. (NYSE: PKI), a global technology leader in Health
Sciences and Photonics, today announced that John E. Sherwin, Ph.D., has
joined the Company as director of laboratory operations for its genetic
screening business, reporting to Ann-Christine Sundell, president of
genetic screening, PerkinElmer, Inc. In this role, he is responsible for
overseeing and directing the growth of PerkinElmer’s
genetic screening laboratory services offerings, including PerkinElmer
Genetics, Inc., a neonatal screening reference laboratory, and NTD
Laboratories, a reference laboratory specializing in prenatal risk
assessment.
Dr. Sherwin brings more than 30 years of pediatric and perinatal
laboratory medicine experience to his new position, including nearly 20
years directing laboratories at hospitals in Chicago and Fresno,
California. He joins PerkinElmer from the State of California, where he
most recently served as acting chief of the Genetic Disease Branch,
responsible for the operation of the State’s
entire prenatal and newborn screening program –
the largest such program in the world. Prior to this, he was chief of
the California Genetic Disease Laboratory for eight years. He has also
held positions as senior technical director, general manager and chief
operating officer of multimillion-dollar reference laboratories and has
been a consultant to a variety of businesses and physician practices.
"John is a talented clinician and seasoned
laboratory director with the scientific and operations expertise needed
to lead our genetic screening reference laboratories,”
said Sundell. "We are fortunate to have someone with John’s
experience join our team as we continue to expand our world-class
neonatal and prenatal/maternal health solutions and services portfolio
to help protect the health of mothers and babies around the world from
pregnancy to birth and beyond.”
Dr. Sherwin is a past president of both the American Association for
Clinical Chemistry and the National Academy of Clinical Biochemistry, is
active in the Association of Public Health Laboratories, and is a member
of the governing council of the International Society for Newborn
Screening. He holds a Ph.D. in biological science from the University of
California, Santa Barbara and a bachelor’s
degree in biology from the University of Arizona, Tucson.
Factors Affecting Future Performance
This press release contains "forward-looking”
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including, but not limited to, statements relating
to estimates and projections of future earnings per share, cash flow,
revenue growth and other financial results, developments relating to our
customers and end-markets, and plans concerning business development
opportunities. Words such as "believes,” "intends,” "anticipates,” "plans,” "expects,” "projects,” "forecasts,” "will” and similar
expressions, and references to guidance, are intended to identify
forward-looking statements. Such statements are based on management’s
current assumptions and expectations and no assurances can be given that
our assumptions or expectations will prove to be correct. A number of
important risk factors could cause actual results to differ materially
from the results described, implied or projected in any forward-looking
statements. These factors include, without limitation: (1) our failure
to introduce new products in a timely manner; (2) our ability to execute
acquisitions and license technologies, or to successfully integrate
acquired businesses and licensed technologies into our existing business
or to make them profitable; (3) our failure to protect adequately our
intellectual property; (4) the loss of any of our licenses or licensed
rights; (5) our ability to compete effectively; (6) fluctuation in our
quarterly operating results and our ability to adjust our operations to
address unexpected changes; (7) our ability to produce an adequate
quantity of products to meet our customers’
demands; (8) our failure to maintain compliance with applicable
government regulations; (9) regulatory changes; (10) our failure to
comply with health care industry regulations; (11) economic, political
and other risks associated with foreign operations; (12) our ability to
retain key personnel; (13) restrictions in our credit agreements; (14)
our ability to realize the full value of our intangible assets; and (15)
other factors which we describe under the caption "Risk
Factors” in our most recent annual report on
Form 10-K and in our most recent quarterly report on Form 10-Q and in
our other filings with the Securities and Exchange Commission. We
disclaim any intention or obligation to update any forward-looking
statements as a result of developments occurring after the date of this
press release.
PerkinElmer, Inc. is a global technology leader driving growth and
innovation in Health Sciences and Photonics markets to improve the
quality of life. The Company reported revenues of $1.8 billion in 2007,
has 9,100 employees serving customers in more than 150 countries, and is
a component of the S&P 500 Index. Additional information is
available through www.perkinelmer.com
or 1-877-PKI-NYSE.
Bookmarken
